Keyword: Mitsubishi Tanabe Pharma
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
How do you get 100% of the payers you approach to cover a pricey new med? Mitsubishi Tanabe’s commercial chief has an idea.
Samsung launched Remicade biosimilar, Mitsubishi Tanabe bought NeuroDerm for $1.1 billion, Takeda made a drug discovery deal.
Wockhardt reported a widened Q4 loss, Takeda penned a T-cell platform deal, and the FDA approved Mitsubishi’s ALS drug Radicava.
The FDA actually invited Mitsubishi Tanabe to file Radicava for U.S. approval based on data generated in Japan. Now, it's the first new ALS med in decades.
As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share.
With Mitsubishi Tanabe deal, Sun Pharma takes a basket of new meds into Japan, a market where Indian drugmakers are under-represented.
Mitsubishi Tanabe is hoping to end a 20-year drought in the U.S. for new ALS medicines.